Twist Bioscience Co. (NASDAQ:TWST) COO Sells $55,840.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 1,877 shares of Twist Bioscience stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $55,840.75. Following the sale, the chief operating officer now owns 240,783 shares of the company's stock, valued at approximately $7,163,294.25. This represents a 0.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Monday, May 5th, Patrick John Finn sold 2,800 shares of Twist Bioscience stock. The shares were sold at an average price of $37.65, for a total value of $105,420.00.
• On Wednesday, April 23rd, Patrick John Finn sold 2,058 shares of Twist Bioscience stock. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42.
• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total value of $7,978.38.

Twist Bioscience Stock Performance

Twist Bioscience stock traded down $1.08 during mid-day trading on Wednesday, reaching $28.33. The company had a trading volume of 1,142,745 shares, compared to its average volume of 978,754. Twist Bioscience Co. has a 52 week low of $27.12 and a 52 week high of $60.90. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -8.38 and a beta of 2.54. The company has a 50 day moving average of $35.90 and a 200-day moving average of $42.50. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, sell-side analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the topic of a number of recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after buying an additional 9,722 shares during the last quarter. KBC Group NV lifted its position in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Twist Bioscience by 18.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock valued at $807,000 after purchasing an additional 2,755 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.